HPHA — Heidelberg Pharma AG Share Price
0.000.00%
Last trade - 00:00- €139.81m
- €102.21m
- €9.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.83 | ||
| Price to Tang. Book | 3.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 14.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.93% | ||
| Return on Equity | -35.08% | ||
| Operating Margin | -215.13% | ||
Financial Summary
| Year End 30th Nov | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 7.31 | 8.49 | 1.75 | 18.51 | 9.86 | 11.5 | 15 | 21.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.
Directors
- Christof Hettich CSU
- Jan Schmidt-Brand CEO
- Georg Baur VSU
- Andreas Pahl CSO
- Mathias Hothum SUB (54)
- Birgit Kudlek SUB (54)
- Friedrich von Bohlen und Halbach SUB (59)
- Last Annual
- November 30th, 2023
- Last Interim
- November 30th, 2023
- Incorporated
- October 18th, 2017
- Public Since
- November 13th, 2006
- No. of Employees
- 95
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- XETRA
- Shares in Issue
- 46,604,977
- Address
- Schriesheimer Strasse 101, LADENBURG, 68526
- Web
- https://www.heidelberg-pharma.com/
- Phone
- +49 620310090
- Auditors
- Deloitte & Touche GmbH Wirtschaftspruef.
Upcoming Events for HPHA
Q1 2024 Heidelberg Pharma AG Earnings Release
Heidelberg Pharma AG Annual Shareholders Meeting
Heidelberg Pharma AG Annual Shareholders Meeting
Half Year 2024 Heidelberg Pharma AG Earnings Release
Q3 2024 Heidelberg Pharma AG Earnings Release
Similar to HPHA
FAQ
What is the Heidelberg Pharma AG share price?
As of Today at 19:10 UTC, shares in Heidelberg Pharma AG are trading at €3.00. This share price information is delayed by 15 minutes.
How has the Heidelberg Pharma AG share price performed this year?
Shares in Heidelberg Pharma AG last closed at €3.00 and the price had moved by -28.91% over the past 365 days. In terms of relative price strength the Heidelberg Pharma AG share price has underperformed the FTSE Global All Cap Index by -33.26% over the past year.
What are the analyst and broker recommendations for Heidelberg Pharma AG?
The overall consensus recommendation for Heidelberg Pharma AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Heidelberg Pharma AG dividend yield?
Heidelberg Pharma AG does not currently pay a dividend.
Does Heidelberg Pharma AG pay a dividend?
Heidelberg Pharma AG does not currently pay a dividend.
When does Heidelberg Pharma AG next pay dividends?
Heidelberg Pharma AG does not currently pay a dividend.
How do I buy Heidelberg Pharma AG shares?
To buy shares in Heidelberg Pharma AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Heidelberg Pharma AG?
As of the previous close price of €3.00, shares in Heidelberg Pharma AG had a market capitalisation of €139.81m.
Where are Heidelberg Pharma AG shares listed?
Here are the trading details for Heidelberg Pharma AG:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: HPHA
What kind of share is Heidelberg Pharma AG?
Based on an overall assessment of its quality, value and momentum Heidelberg Pharma AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Heidelberg Pharma AG share price forecast for 2024?
The analyst consensus target price for shares in Heidelberg Pharma AG is €11.30. That is 276.67% above the last closing price of €3.00.
Analysts covering Heidelberg Pharma AG currently have a consensus Earnings Per Share (EPS) forecast of -€0.59 for the next financial year.
What is the trend in the Heidelberg Pharma AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Heidelberg Pharma AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -16.89%.
As of the last closing price of €3.00, shares in Heidelberg Pharma AG were trading -7.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Heidelberg Pharma AG PE Ratio?
The Heidelberg Pharma AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €3.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Heidelberg Pharma AG?
Heidelberg Pharma AG's management team is headed by:
- Christof Hettich - CSU
- Jan Schmidt-Brand - CEO
- Georg Baur - VSU
- Andreas Pahl - CSO
- Mathias Hothum - SUB
- Birgit Kudlek - SUB
- Friedrich von Bohlen und Halbach - SUB